<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.02">
 <iati-activity hierarchy="1" iati-activities:version="2.02" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>XM-DAC-903-SII-39029</iati-identifier>
  <reporting-org ref="XM-DAC-903" type="40">
   <narrative xml:lang="EN">International Finance Corporation</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Carnelian Project</narrative>
  </title>
  <description type="2">
   <narrative xml:lang="EN">The Project&apos;s expected development impacts include: (i) increasing access to affordable quality medicines, (ii) enabling a regional consolidator to increase access to medicines through efficient distribution and increased quality standards, (iii) increasing global competitiveness of a local manufacturer, (iv) contributing toward gender employment, and (v) reducing counterfeiting of medicines through the development of innovative advance delivery technologies.</narrative>
  </description>
  <description type="1">
   <narrative xml:lang="EN">The project consists of an equity investment of up to USD 90 million into the Unimed Pharmaceuticals Limited and Sofgen Pharmaceuticals LLC (the Group), a Life Sciences group of companies with operations across Latin America, to support its expansion in the region. The Groups key subsidiary is Procaps SA based in Colombia.</narrative>
  </description>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">UNIMED PHARMACEUTICALS LIMITED</narrative>
  </participating-org>
  <participating-org activity-id="XM-DAC-903-SII-39029" ref="XM-DAC-903" role="1" type="40"></participating-org>
  <activity-status code="2"></activity-status>
  <activity-date iso-date="2017-09-01" type="1"></activity-date>
  <activity-date iso-date="2017-09-20" type="2"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">International Finance Corporation</narrative>
   </organisation>
   <telephone>+12024733800</telephone>
   <email>ccspg@ifc.org</email>
   <website>www.ifc.org</website>
   <mailing-address>
    <narrative xml:lang="EN">2121 Pennsylvania Avenue, NW Washington DC 20433</narrative>
   </mailing-address>
  </contact-info>
  <contact-info type="2">
   <mailing-address>
    <narrative xml:lang="EN">Procaps SA  Eduardo Herrera  VP Plants and Operations  5753719253  eherrera@procapsgroup.com  Calle 80 # 78B  201, Barranquilla, Colombia  www.procapslaboratorios.com</narrative>
   </mailing-address>
  </contact-info>
  <contact-info type="2">
   <mailing-address>
    <narrative xml:lang="EN">table, .k-table{ border-collapse:collapse; width:100%; table-layout:fixed; margin-bottom: 15px;} .k-table, .k-table td, table, table td {outline: 0;border: 1px solid #000; } .k-table td, table td { padding: 5px; }        Contact Person: Eduardo Herrera        Company Name: Procaps S.A.        Disclosure Address: Calle 80 # 78B  201         Email: eherrera@procapsgroup.com        Phone: 5753719253        City: Barranquilla         Country: Colombia        &#xA0;        Contact Person: Mauricio Casta&#xF1;eda        Company Name: Procaps S.A.        Disclosure Address: Calle 80 # 78B  201           Email: mcastaneda@procapsgroup.com        Phone: 5753719301         &#xA0;        Contact Person: Eduardo Herrera    &#xA0;      Company Name: Alinova        Disclosure Address: Av. Boyaca 23  66        Email: eherrera@procapsgroup.com        Phone: 5753719253        City: Bogota        Country: Colombia        &#xA0;        Contact Person: Eduardo Herrera        Company Name: Pharmayect        Disclosure Address: Cra. 129 # 22b  57, Bogot&#xE1;        Email: eherrera@procapsgroup.com        Phone: 5753719253        City: Bogota        Country: Colombia        &#xA0;        Contact Person: Eduardo Herrera        Company Name: Laboratorios Lopez        Disclosure Address: Boulevard del Ej&#xE9;rcito Nacional, Km. 5 1/2, apartado postal 285        Email: eherrera@procapsgroup.com        Phone: 5753719253        City: San Salvador        Country: El Salvador        &#xA0;        Contact Person: Eduardo Herrera        Company Name: Biokemical        Disclosure Address: Kil&#xF3;metro 17 1/2 Calle Alberto Masferrer 174-A Barrio Las Mercedes Santo Tomas        Email: eherrera@procapsgroup.com        Phone: 5753719253        City: San Salvador        Country: El Salvador        &#xA0;        Contact Person: Eduardo Herrera        Company Name: Softcaps        Disclosure Address: Estrada dos Estudantes, 349, Cotia, 06707-050           Email: eherrera@procapsgroup.com        Phone: 5753719253        City: Sao Paulo        Country: Brazil</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="CO" percentage="100">
   <narrative xml:lang="EN">Colombia</narrative>
  </recipient-country>
  <location ref="CO-Colombia">
   <location-reach code="1"></location-reach>
   <location-id code="1453782" vocabulary="G1"></location-id>
   <name>
    <narrative xml:lang="EN">table, .k-table{ border-collapse:collapse; width:100%; table-layout:fixed; margin-bottom: 15px;} .k-table, .k-table td, table, table td {outline: 0;border: 1px solid #000; } .k-table td, table td { padding: 5px; }        The Groups headquarter are in Barranquilla, Colombia. IFCs proceeds will be used across Colombia, Brazil, El Salvador and Ecuador.</narrative>
   </name>
   <description>
    <narrative xml:lang="EN">Location description</narrative>
   </description>
   <activity-description>
    <narrative xml:lang="EN">A description that qualifies the activity taking place at the location.</narrative>
   </activity-description>
   <administrative code="1453782" level="1" vocabulary="G1"></administrative>
   <point srsName="http://www.opengis.net/def/crs/EPSG/0/4326">
    <pos>4.0000000000 -73.2500000000</pos>
   </point>
   <exactness code="2"></exactness>
   <location-class code="1"></location-class>
   <feature-designation code="ADMF"></feature-designation>
  </location>
  <sector code="325" percentage="100" vocabulary="11" vocabulary-uri="http://www.census.gov/cgi-bin/sssd/naics/naicsrch?chart=2012">
   <narrative xml:lang="EN">G-FA - Pharmaceuticals and Medicine Manufacturing</narrative>
  </sector>
  <country-budget-items vocabulary="1">
   <budget-item code="7.2.1" percentage="100" vocabulary="1">
    <description>
     <narrative xml:lang="EN">Total: $90.00 million</narrative>
    </description>
   </budget-item>
  </country-budget-items>
  <collaboration-type code="6"></collaboration-type>
  <default-flow-type code="35"></default-flow-type>
  <default-finance-type code="510"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget type="1">
   <period-start iso-date="2017-09-01"></period-start>
   <period-end iso-date="2018-06-30"></period-end>
   <value currency="USD" value-date="2017-09-01">90000000</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2017-09-01"></transaction-date>
   <value currency="USD" value-date="2017-09-01">90000000</value>
   <receiver-org>
    <narrative xml:lang="EN">UNIMED PHARMACEUTICALS LIMITED</narrative>
   </receiver-org>
   <flow-type code="35"></flow-type>
   <finance-type code="510"></finance-type>
  </transaction>
  <document-link format="TEXT/HTML" url="https://disclosures.ifc.org/project-detail/SII/39029/carnelian-project">
   <title>
    <narrative xml:lang="EN">Summary of Investment Information - Anticipated Impact Measurement &amp; Monitoring (AIMM) Assessment and Main Environmental &amp; Social Risks and Impacts of the Project</narrative>
   </title>
   <category code="A01"></category>
   <language code="EN"></language>
  </document-link>
  <document-link format="TEXT/HTML" url="https://disclosures.ifc.org/project-detail/SII/39029/carnelian-project">
   <title>
    <narrative xml:lang="EN">Summary of Investment Information</narrative>
   </title>
   <category code="A12"></category>
   <language code="EN"></language>
  </document-link>
  <result aggregation-status="1" type="1">
   <title>
    <narrative xml:lang="EN">Development Results</narrative>
   </title>
   <description>
    <narrative xml:lang="EN">Development Result Description</narrative>
   </description>
   <indicator ascending="1" measure="1">
    <title>
     <narrative xml:lang="EN">Indicator</narrative>
    </title>
    <description>
     <narrative xml:lang="EN">Occupational Health and Safety(%)</narrative>
    </description>
    <reference code="Occupational Health and Safety(%)" vocabulary="8"></reference>
    <baseline value="In Progress" year="2019">
     <comment>
      <narrative xml:lang="EN">Occupational Health and Safety(%)</narrative>
     </comment>
    </baseline>
    <period>
     <period-start iso-date="2019-01-01"></period-start>
     <period-end iso-date="2019-12-31"></period-end>
     <target value="0">
      <location ref="CO-Colombia"></location>
      <comment>
       <narrative xml:lang="EN">The Project&apos;s expected development impacts include: (i) increasing access to affordable quality medicines, (ii) enabling a regional consolidator to increase access to medicines through efficient distribution and increased quality standards, (iii) increasing global competitiveness of a local manufacturer, (iv) contributing toward gender employment, and (v) reducing counterfeiting of medicines through the development of innovative advance delivery technologies.</narrative>
      </comment>
     </target>
     <actual value="In Progress">
      <location ref="CO-Colombia"></location>
      <comment>
       <narrative xml:lang="EN">The Project&apos;s expected development impacts include: (i) increasing access to affordable quality medicines, (ii) enabling a regional consolidator to increase access to medicines through efficient distribution and increased quality standards, (iii) increasing global competitiveness of a local manufacturer, (iv) contributing toward gender employment, and (v) reducing counterfeiting of medicines through the development of innovative advance delivery technologies.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
   <indicator ascending="1" measure="1">
    <title>
     <narrative xml:lang="EN">Indicator</narrative>
    </title>
    <description>
     <narrative xml:lang="EN">Organizational capacity and Management Programs(%)</narrative>
    </description>
    <reference code="Organizational capacity and Management Programs(%)" vocabulary="8"></reference>
    <baseline value="In Progress" year="2019">
     <comment>
      <narrative xml:lang="EN">Organizational capacity and Management Programs(%)</narrative>
     </comment>
    </baseline>
    <period>
     <period-start iso-date="2019-01-01"></period-start>
     <period-end iso-date="2019-12-31"></period-end>
     <target value="0">
      <location ref="CO-Colombia"></location>
      <comment>
       <narrative xml:lang="EN">The Project&apos;s expected development impacts include: (i) increasing access to affordable quality medicines, (ii) enabling a regional consolidator to increase access to medicines through efficient distribution and increased quality standards, (iii) increasing global competitiveness of a local manufacturer, (iv) contributing toward gender employment, and (v) reducing counterfeiting of medicines through the development of innovative advance delivery technologies.</narrative>
      </comment>
     </target>
     <actual value="In Progress">
      <location ref="CO-Colombia"></location>
      <comment>
       <narrative xml:lang="EN">The Project&apos;s expected development impacts include: (i) increasing access to affordable quality medicines, (ii) enabling a regional consolidator to increase access to medicines through efficient distribution and increased quality standards, (iii) increasing global competitiveness of a local manufacturer, (iv) contributing toward gender employment, and (v) reducing counterfeiting of medicines through the development of innovative advance delivery technologies.</narrative>
      </comment>
     </actual>
    </period>
   </indicator>
  </result>
 </iati-activity>
</iati-activities>
